BCL2 and myelodysplastic syndrome: As single agents, DNMTi are currently approved for treatment of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) [109]; in AML, also in combination with the BCL2 inhibitor venetoclax [110].